Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832006 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL283357 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL713247 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL11339365 | 0.88 | TSHR (0.56) | ALDH1A1TSHRADAM17NFKB1TP53 | |
| SCHEMBL16356392 | 0.88 | ADAM17 (0.33) | ALDH1A1TSHRADAM17 | |
| SCHEMBL18902855 | 0.86 | ADAM17 (0.33) | ALDH1A1TSHRADAM17 | |
| SCHEMBL7259228 | 0.86 | ADAM17 (0.33) | ALDH1A1TSHRADAM17 | |
| SCHEMBL21631865 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL8284890 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRADAM17NFKB1THPO | |
| SCHEMBL12000465 | 0.84 | ALDH1A1 (0.33) | ALDH1A1TSHRADAM17NFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279225-A1 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-22 | — | — | US | disclosed |
| EP-4319755-A1 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | Board of Regents, The University of Texas System (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216979-A1 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | Io Therapeutics, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-18 | — | — | US | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-10590059-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | Io Therapeutics, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | ABBVIE INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007150010-A2 | CYCLOPROPYL AMINE DERIVATIVES AS HISTAMIN H3 RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
| US-7169544-B2 | Thermally developable materials containing thermal solvents | EASTMAN KODAK COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169544-B2 | Thermally developable materials containing thermal solvents | EASTMAN KODAK COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-6818778-B2 | HYDROLYSIS OF OCTAETHYL(-)-(18-CROWN-6)-2,3,11,12-TETRACARBOXAMIDE OBTAINED BY CONDENSATION OF N,N,N',N'-TETRAALKYL-D-TARTARAMIDE WITH DIHALO- OR DISULFONYLOXY- DIETHYL ETHER | RSTECH CO., LTD. (KR) | 2004-11-16 | — | — | US | disclosed |
| US-20040044231-A1 | Process for preparing (-)-(18-crown-6)-2,3,11,12-tetracarboxylic acid, and (-)-chiral stationary phases for resolution of racemic compounds using the same | RSTECH CO., LTD. (KR) | 2004-03-04 | — | — | US | disclosed |
| WO-2002042288-A1 | PROCESS FOR PREPARING (-)-(18-CROWN-6)-2,3,11,12-TETRACARBOXYLIC ACID, AND (-)-CHIRAL STATIONARY PHASES FOR RESOLUTION OF RACEMIC COMPOUNDS USING THE SAME | RSTECH CO., LTD (KR) | 2002-05-30 | — | — | WO | disclosed |
| US-5994479-A | Curable coating compositions containing blends of carbamate-functional compounds | BASF CORPORATION (US) | 1999-11-30 | — | — | US | disclosed |
| US-5854385-A | Coating compositions with low molecular weight carbamate or urea component | BASF CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0767187-A1 | Coating compositions with low molecular weight carbamate of urea component | BASF CORPORATION (US) | 1997-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190008-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | ALDH1A1 835/4885TSHR 53/4885ADAM17 3776/4885 |
| US-20080021081-A1 | e.g. 4'-2-{[(2S)-2-methylpyrrolidin-1-yl]methyl}cyclopropyl)-1,1'-biphenyl-4-carbonitrile; histamine-3 receptor ligand; neuroleptic agent, neurodegenerative diseases, cognition activator; attention-deficit hyperactivity disorder, schizophrenia, Alzheimer's disease, epilepsy, seizures, allergic rhinitis | HRH4, HRH3, HNMT | ALDH1A1 852/4885TSHR 1156/4885ADAM17 2345/4885 |
| US-20240279225-A1 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | PARP8, PARP1, PARP3 | ALDH1A1 2204/4885TSHR 1586/4885ADAM17 777/4885 |
| US-10590059-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | ALDH1A1 835/4885TSHR 53/4885ADAM17 3776/4885 |
| US-20040044231-A1 | Process for preparing (-)-(18-crown-6)-2,3,11,12-tetracarboxylic acid, and (-)-chiral stationary phases for resolution of racemic compounds using the same | CCR6, CCR1, CCR9 | ALDH1A1 519/4885TSHR 1402/4885ADAM17 1487/4885 |
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | ALDH1A1 4208/4885TSHR 3296/4885ADAM17 1522/4885 |
| US-10919835-B2 | Compounds and synthetic methods for the preparation of retinoid X receptor-specific retinoids | RXRG, RXRB, RXRA | ALDH1A1 835/4885TSHR 53/4885ADAM17 3776/4885 |
| US-20210139404-A1 | COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS | RXRG, RXRB, RXRA | ALDH1A1 835/4885TSHR 53/4885ADAM17 3776/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | ALDH1A1 3255/4885TSHR 3179/4885ADAM17 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.